The new InhaLac® 160 is characterized by a median particle size of approximately 110 µm which ranges between the coarser lacotse InhaLac® 120 and the finer lactose InhaLac® 230. This excipient exhibits a narrowly distributed particle size with a fine particle fraction of 3%. InhaLac® 160 expands the product line of sieved lactose grades for dry powder inhalation. Inhalation aerosols offers the potential for needle-free systemic delivery of small molecule drugs as well as therapeutic peptides and proteins. An industry standard in dry power inhalation formulation development, lactose monohydrate is used safely in DPI formulations. Using lactose as an excipient not only improves performance efficiency of the inhaler, but also facilitates powder handling during production. Effective performance of a dry powder inhaler largely depends on the carrier material used for the drug formulation. With our highly controlled production process different high quality sieved and milled grades are obtained, providing an adequate range of particle sizes – making them behave as individual particles. Particle size distribution [Laser diffraction] x10: 55-85 µm x50: 90-120 µm x90: 125-165 µm Typical Values Bulk Density [g/l]: 700 Tapped Density [g/l] : 835 Hausner factor: 1.19 Carrs index: 16 %
Generic and alternative namesLactose Monohydrate, Inhalation
Claims / benefits / efficacyDedicated production process Highly controlled powder characteristics Highest microbial quality including low endotoxins Retests after 24 months
ApplicationInhaLac® 160 as a sieved lactose is suitable for use in pulmonary and nasal drug delivery.